Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. (NY: SNY )

43.41 USD UNCHANGED
Last Price Updated: 5:16 PM EST, Dec 31, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Sanofi-Aventis S.A.

< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Genzyme's Lemtrada Approved in Canada for Treatment of MS
Genzyme, a Sanofi company (NYSE: SNY ), announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis (RRMS), 
Tags Guidance Benzinga Global
From Benzinga
Genzyme’s Lemtrada™ Approved in Canada for Treatment of Multiple Sclerosis
From Business Wire News Releases
Published Data, Stock Price Movements, and FDA Approvals - Research Report on Johnson & Johnson, Ariad Pharmaceuticals, PerkinElmer, BD, and Sanofi
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
4 ways to make Money off Washington next year
Next year is an election year. There is little chance of a significant tax increase, or a government shutdown or debt crisis. 
Tags Johnson and Johnson Lockheed Martin Corp Agilent techonologies Inc
From CNBC.com News
FDA Grants Priority Review for Genzyme's Cerdelga for Gaucher Disease
Genzyme, a Sanofi company (NYSE: SNY ), announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application 
Tags Global Benzinga Guidance
From Benzinga
FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease
From Business Wire News Releases
ImmunoGen to expand Waltham headquarters by 20 percent
Despite a recent decision to stop work on what had been its most promising potential cancer drug, ImmunoGen says it's expanding its Waltham headquarters by about 20 percent starting next summer to... 
Tags Health Care Eli Lilly Sanofi
From Business Journals
Sanofi US Launches Second Innovation Challenge: Collaborate | Innovate
Developing approaches for involving patients in drug development 
From PR Newswire
Sundance Energy Corporation: Ochapowace 16-32-17-3W2M: Drilling Update
From Marketwired
New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia®
- Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal - 
From PR Newswire
Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
From PR Newswire
The Multiple Sclerosis Association of America Announces Swim for MS - Why I Swim Campaign
From PR Newswire
Notable Two Hundred Day Moving Average Cross - SNY
In trading on Tuesday, shares of Sanofi (SNY) crossed below their 200 day moving average of $51.57, changing hands as low as $51.16 per share. Sanofi shares are currently trading down about 1.5% on the... 
Tags Stocks
From Market News Video
Market Study: VIVUS, DENTSPLY Intl., Sanofi, and Healthways Inc.
Editor Note: For more information about this release, please scroll to bottom 
From PR Newswire
Sanofi Announces New Phase 3 Results for Investigational New Insulin U300
- EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus® - 
From PR Newswire
Hagens Berman: Statement of Steve W. Berman, lead attorney in US-Based Thalidomide Cases, in Response to Recent $81 million settlement for Australian victims
From Business Wire News Releases
CFO of Aveo to resign seven months after drug failure
The chief financial officer of Aveo Oncology, who helped bring the Cambridge company public in 2010 and has stayed on since the company’s stock crashed this spring following the rejection of its lead... 
Tags Ford Motor Co/ Genzyme Corp/ Biotech
From Business Journals
Alnylam gets $7M milestone from Genzyme for rare disease drug
Alnylam Pharmaceuticals has received a $7 million milestone payment from partner Genzyme Corp. for its most advanced drug for a rare, inherited heart disease, following recently-released results from a... 
Tags Biotech Genzyme Corp/ U/S/ Food and Drug Administration
From Business Journals
FDA Approvals, New Appointments, and Official Statements - Research Report on Pfizer, Aetna, Lilly, GSK, and Sanofi
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Merrimack's stock rises on breast cancer data, new agreement
Merrimack Pharmaceuticals today reported results of two mid-stage studies of a cancer drug, showing effectiveness in two subsets of breast cancer patients and driving the company’s stock up more than... 
Tags Merrimack Pharmaceuticals Health Care Gavin MacBeath
From Business Journals
Sanofi and Regeneron's Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
From PR Newswire
Trend Analysis Report on - Sanofi SA (ADR) (NYSE:SNY), SunTrust Banks, Inc. (NYSE:STI), Weyerhaeuser Company (NYSE:WY), Yelp Inc (NYSE:YELP)
New York, NY -- (SBWIRE) -- 11/23/2013 -- StockMarketIntel.com issues a special report on the following stocks: Sanofi SA (ADR) (NYSE:SNY), SunTrust Banks, Inc. (NYSE:STI), Weyerhaeuser Company... 
From SBWire - Latest Press Releases
Sundance Energy Announces Resignation of Director
From Marketwired
Sanofi, Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Sanofi (NYSE: SNY ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) today announced that in the SARIL-RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were... 
Tags Benzinga News REGN
From Benzinga
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints 
From PR Newswire
Genzyme Convenes 5th Annual Gaucher Leadership Forum in Madrid
From Business Wire News Releases
Health Canada Approves Genzyme's AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis
From PR Newswire
Clinical Trial Results, New Products, Employee Grants, Pricing of Offering - Research Report on GSK, Intuitive, IDEXX, Sanofi, and Foundation Medicine
Editor Note: For more information about this release, please scroll to bottom. 
From PR Newswire
Small step for BioMarin could mean leap for rare disease patients
A few steps stand between BioMarin Pharmaceutical Inc. and another rare disease drug approval. The San Rafael-based drug developer (NASDAQ: BMRN) believes improvements in a six-minute walking test by... 
Tags Jean/Jacques Bienaimé Stephanie Bozarth Health Care
From Business Journals
2013 3Q 13F Roundup
On November 14, many institutional investment managers and major hedge funds reported their 13F form. A 13F form is a quarterly report of equity holdings filed by institutional investment managers with... 
Tags OIS DTV US8835561023
From Benzinga
< Previous 1 2
...
93 94 95 96 97 98 99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback